IS5696A - Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra - Google Patents

Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra

Info

Publication number
IS5696A
IS5696A IS5696A IS5696A IS5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A
Authority
IS
Iceland
Prior art keywords
derivatives
antibodies against
therapeutic use
therapeutic
antibodies
Prior art date
Application number
IS5696A
Other languages
English (en)
Inventor
Marcel Paul Bonnefoy Jean-Yves
James Crowe Scott
Henry Ellis Jonathan
Timothy Rapson Nicholas
Shearin Jean
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5696A publication Critical patent/IS5696A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS5696A 1998-05-09 2000-10-31 Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra IS5696A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
IS5696A true IS5696A (is) 2000-10-31

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5696A IS5696A (is) 1998-05-09 2000-10-31 Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra

Country Status (25)

Country Link
US (1) US7008623B1 (is)
EP (1) EP1076701A1 (is)
JP (1) JP2002514421A (is)
KR (1) KR20010043470A (is)
CN (1) CN1308676A (is)
AP (1) AP1547A (is)
AU (1) AU763491B2 (is)
BR (1) BR9910327A (is)
CA (1) CA2328606A1 (is)
EA (1) EA200001041A1 (is)
EE (1) EE200000658A (is)
GB (1) GB9809839D0 (is)
HR (1) HRP20000762A2 (is)
HU (1) HUP0102005A3 (is)
ID (1) ID28088A (is)
IL (1) IL139384A0 (is)
IS (1) IS5696A (is)
NO (1) NO20005632L (is)
NZ (1) NZ507879A (is)
PL (1) PL344019A1 (is)
SK (1) SK16762000A3 (is)
TR (1) TR200003281T2 (is)
WO (1) WO1999058679A1 (is)
YU (1) YU69000A (is)
ZA (1) ZA200006312B (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EP1326897A2 (en) 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
TW200416044A (en) * 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
JP2007521248A (ja) * 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
RS20080200A (en) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
CA2706419A1 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs binding il-13
BRPI0907135B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
KR20110015604A (ko) 2008-05-06 2011-02-16 글락소 그룹 리미티드 생물학적 활성제의 캡슐화
CA2753263A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
EP2401297A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2414393A1 (en) 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
CA2758842A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Fgfr1c antibody combinations
RU2535074C2 (ru) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
CN103328508B (zh) 2010-11-23 2015-12-16 葛兰素集团有限公司 针对制癌蛋白m(osm)的抗原结合蛋白
EA201390611A1 (ru) 2010-11-24 2014-01-30 Глаксо Груп Лимитед Мультиспецифические антигенсвязывающие белки, направленные на hgf
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
MA38498B1 (fr) 2013-03-15 2018-11-30 Glaxosmithkline Ip Dev Ltd Protéines de liaison anti-lag-3
JP6440036B2 (ja) * 2013-07-10 2018-12-19 オンコノックス エーピーエス 抗β２−グリコプロテインＩ抗体及びその治療的用法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
DK3119431T3 (da) 2014-03-21 2024-03-18 Teva Pharmaceuticals Int Gmbh Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
CN117510633A (zh) 2015-09-02 2024-02-06 伊缪泰普有限公司 抗lag-3抗体
US10479827B2 (en) * 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
BR112021023048A2 (pt) 2019-05-21 2022-04-19 Novartis Ag Moléculas de ligação a cd19 e usos das mesmas
US20230295313A1 (en) 2019-06-26 2023-09-21 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233011T2 (de) 1991-07-25 2003-11-06 Idec Pharmaceuticals Corp., San Diego Rekombinante antikörper zur humanen therapie
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
CA2203363A1 (en) * 1994-10-25 1996-05-02 Jean-Yves Marcel Paul Bonnefoy Binding agents to cd23
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
US7008623B1 (en) 2006-03-07
AU3836799A (en) 1999-11-29
PL344019A1 (en) 2001-09-24
BR9910327A (pt) 2001-01-30
CA2328606A1 (en) 1999-11-18
NZ507879A (en) 2004-02-27
JP2002514421A (ja) 2002-05-21
AP1547A (en) 2006-01-13
EA200001041A1 (ru) 2001-06-25
EP1076701A1 (en) 2001-02-21
AU763491B2 (en) 2003-07-24
TR200003281T2 (tr) 2001-03-21
GB9809839D0 (en) 1998-07-08
NO20005632D0 (no) 2000-11-08
CN1308676A (zh) 2001-08-15
HUP0102005A3 (en) 2003-10-28
WO1999058679A1 (en) 1999-11-18
YU69000A (sh) 2003-08-29
EE200000658A (et) 2002-04-15
HRP20000762A2 (en) 2001-06-30
SK16762000A3 (sk) 2001-07-10
AP2000001983A0 (en) 2000-12-31
IL139384A0 (en) 2001-11-25
ZA200006312B (en) 2003-02-26
ID28088A (id) 2001-05-03
HUP0102005A2 (hu) 2001-10-28
NO20005632L (no) 2001-01-08
KR20010043470A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
IS2277B (is) Meðferðarlegar bíarýl afleiður
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
DK1019358T4 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
NO20013237L (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO986174D0 (no) Triazinderivater og anvendelse derav
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse
NO982549D0 (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav